{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T04:18:49Z","timestamp":1649045929434},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The incidence of angioimmunoblastic T-cell lymphoma is rare worldwide, and it has a poor prognosis. There is no proven or standard first-line therapy that works for the majority of patients with angioimmunoblastic T-cell lymphoma because of the rarity of this disease. The treatment and management are challenging for clinicians.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>This report presents the diagnosis and treatment of a 65-year-old Chinese man who presented with cough and lymph node swellings in the left axillary region. The patient was diagnosed with angioimmunoblastic T-cell lymphoma. He underwent eight\u2009cycles of chemotherapy with CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) followed by TOMO radiotherapy (helical tomotherapy, a kind of radiotherapy for cancer treatment using spiral computed tomographic scanning). After treatment, the therapeutic effects were evaluated by magnetic resonance imaging and computed tomography about every 3\u2009months. The patient recovered well with no sign of tumor recurrence and no obvious severe treatment-related adverse effects.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This treatment experience indicates an essential role for the combination of radiation therapy with CHOP, which may have a better prognosis than treatments without radiation therapy. But challenges warrant further validation in prospective studies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-020-02489-4","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T23:02:56Z","timestamp":1602543776000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chemotherapy combined with radiotherapy for successful treatment of angioimmunoblastic T-cell lymphoma: a case report"],"prefix":"10.1186","volume":"14","author":[{"given":"Yudi","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuxiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"2489_CR1","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"Non-Hodgkin\u2019s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood. 1997;89:3909\u201318.","journal-title":"Blood"},{"key":"2489_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","volume":"148","author":"L de Leval","year":"2010","unstructured":"de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2010;148:673\u201389.","journal-title":"Br J Haematol"},{"key":"2489_CR3","doi-asserted-by":"publisher","first-page":"E361","DOI":"10.3324\/haematol.2015.126300","volume":"100","author":"L de Leval","year":"2015","unstructured":"de Leval L, Parrens M, Le Bras F, Jais JP, Fataccioli V, Martin A, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica. 2015;100:E361\u20134.","journal-title":"Haematologica"},{"key":"2489_CR4","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S0140-6736(74)90553-4","volume":"1","author":"G Frizzera","year":"1974","unstructured":"Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974;1:1070\u20133.","journal-title":"Lancet."},{"key":"2489_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s12185-015-1763-7","volume":"101","author":"Y Kameoka","year":"2015","unstructured":"Kameoka Y, Takahashi N, Itou S, Kume M, Noji H, Kato Y, et al. Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma. Int J Hematol. 2015;101:536\u201342.","journal-title":"Int J Hematol"},{"key":"2489_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/10428190290016926","volume":"43","author":"M Reiser","year":"2002","unstructured":"Reiser M, Josting A, Soltani M, Staib P, Salzberger B, Diehl V, et al. T-cell non-Hodgkin\u2019s lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma. 2002;43:805\u201311.","journal-title":"Leuk Lymphoma"},{"key":"2489_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10147-016-1045-2","volume":"22","author":"H Ma","year":"2017","unstructured":"Ma H, Abdul-Hay M. T-cell lymphomas, a challenging disease: types, treatments, and future. Int J Clin Oncol. 2017;22:18\u201351.","journal-title":"Int J Clin Oncol."},{"key":"2489_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/annonc\/mdm497","volume":"19","author":"L Trumper","year":"2008","unstructured":"Trumper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin\u2019s lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol. 2008;19:538\u201344.","journal-title":"Ann Oncol"},{"key":"2489_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2141.2006.06124.x","volume":"134","author":"HJ Sung","year":"2006","unstructured":"Sung HJ, Kim SJ, Seo HY, Sul HR, Choi JG, Choi IK, et al. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. Br J Haematol. 2006;134:45\u201353.","journal-title":"Br J Haematol"},{"key":"2489_CR10","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3109\/10428194.2012.739286","volume":"54","author":"YY Yao","year":"2013","unstructured":"Yao YY, Tang Y, Zhu Q, Zhuang Y, Cheng YM, Wang L, et al. Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leuk Lymphoma. 2013;54:1194\u2013200.","journal-title":"Leuk Lymphoma"},{"key":"2489_CR11","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00277-013-1880-4","volume":"92","author":"C Binder","year":"2013","unstructured":"Binder C, Ziepert M, Pfreundschuh M, Duhrsen U, Eimermacher H, Aldaoud A, et al. CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. Ann Hematol. 2013;92:1521\u20138.","journal-title":"Ann Hematol"},{"key":"2489_CR12","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","volume":"48","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012;48:3223\u201331.","journal-title":"Eur J Cancer."},{"key":"2489_CR13","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093\u20139.","journal-title":"J Clin Oncol."},{"key":"2489_CR14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","volume":"13","author":"N Mehta","year":"2013","unstructured":"Mehta N, Maragulia JC, Moskowitz A, Hamlin PA, Lunning MA, Moskowitz CH, et al. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk. 2013;13:664\u201370.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2489_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631\u20136.","journal-title":"J Clin Oncol"},{"key":"2489_CR16","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182\u20139.","journal-title":"J Clin Oncol"},{"key":"2489_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","volume":"31","author":"G Damaj","year":"2013","unstructured":"Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31:104\u201310.","journal-title":"J Clin Oncol"},{"key":"2489_CR18","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123:3095\u2013100.","journal-title":"Blood."},{"key":"2489_CR19","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1002\/cncr.25377","volume":"116","author":"G Dueck","year":"2010","unstructured":"Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer. 2010;116:4541\u20138.","journal-title":"Cancer."},{"key":"2489_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3109\/10428199909058412","volume":"32","author":"P Pautier","year":"1999","unstructured":"Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini JM, et al. Angioimmunoblastic-like T-cell non Hodgkin\u2019s lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma. 1999;32:545\u201352.","journal-title":"Leuk Lymphoma"},{"key":"2489_CR21","doi-asserted-by":"publisher","first-page":"S236","DOI":"10.1016\/S0167-8140(16)31746-7","volume":"119 Suppl 1","author":"J Yahalom","year":"2016","unstructured":"Yahalom J. Indications to radiotherapy for lymphoma in 2016: what is standard of care and what remains controversial? [abstract]. Radiother Oncol. 2016;119 Suppl 1:S236.","journal-title":"Radiother Oncol."}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02489-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-020-02489-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02489-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T02:55:41Z","timestamp":1634093741000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02489-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2489"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02489-4","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"31 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved by Zhongnan Hospital of Wuhan University. Informed consent was obtained from the patient for the publication of this case report and any accompanying images.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}